These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35275912)

  • 21. Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity.
    Okan NA; Chalabaev S; Kim TH; Fink A; Ross RA; Kasper DL
    mBio; 2013 Feb; 4(1):e00638-12. PubMed ID: 23404403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.
    Cole LE; Elkins KL; Michalek SM; Qureshi N; Eaton LJ; Rallabhandi P; Cuesta N; Vogel SN
    J Immunol; 2006 Jun; 176(11):6888-99. PubMed ID: 16709849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.
    Sebastian S; Pinkham JT; Lynch JG; Ross RA; Reinap B; Blalock LT; Conlan JW; Kasper DL
    Vaccine; 2009 Jan; 27(4):597-605. PubMed ID: 19022323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.
    Chen W; Shen H; Webb A; KuoLee R; Conlan JW
    Vaccine; 2003 Sep; 21(25-26):3690-700. PubMed ID: 12922099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.
    Pechous R; Celli J; Penoske R; Hayes SF; Frank DW; Zahrt TC
    Infect Immun; 2006 Aug; 74(8):4452-61. PubMed ID: 16861631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Francisella tularensis Schu S4 lipopolysaccharide core sugar and O-antigen mutants are attenuated in a mouse model of tularemia.
    Rasmussen JA; Post DM; Gibson BW; Lindemann SR; Apicella MA; Meyerholz DK; Jones BD
    Infect Immun; 2014 Apr; 82(4):1523-39. PubMed ID: 24452684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intranasal vaccination induces protective immunity against intranasal infection with virulent Francisella tularensis biovar A.
    Wu TH; Hutt JA; Garrison KA; Berliba LS; Zhou Y; Lyons CR
    Infect Immun; 2005 May; 73(5):2644-54. PubMed ID: 15845466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aim2 and Nlrp3 Are Dispensable for Vaccine-Induced Immunity against Francisella tularensis Live Vaccine Strain.
    Alqahtani M; Ma Z; Fantone K; Malik M; Bakshi CS
    Infect Immun; 2021 Jun; 89(7):e0013421. PubMed ID: 33875472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
    Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
    Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunoproteomics analysis of the murine antibody response to vaccination with an improved Francisella tularensis live vaccine strain (LVS).
    Twine SM; Petit MD; Fulton KM; House RV; Conlan JW
    PLoS One; 2010 Apr; 5(4):e10000. PubMed ID: 20368994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility of various mouse strains to systemically- or aerosol-initiated tularemia by virulent type A Francisella tularensis before and after immunization with the attenuated live vaccine strain of the pathogen.
    Shen H; Chen W; Conlan JW
    Vaccine; 2004 Jun; 22(17-18):2116-21. PubMed ID: 15149767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.
    Bakshi CS; Malik M; Mahawar M; Kirimanjeswara GS; Hazlett KR; Palmer LE; Furie MB; Singh R; Melendez JA; Sellati TJ; Metzger DW
    Vaccine; 2008 Sep; 26(41):5276-88. PubMed ID: 18692537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge.
    Cong Y; Yu JJ; Guentzel MN; Berton MT; Seshu J; Klose KE; Arulanandam BP
    Vaccine; 2009 Sep; 27(41):5554-61. PubMed ID: 19651173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
    Green M; Choules G; Rogers D; Titball RW
    Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes.
    Santiago AE; Cole LE; Franco A; Vogel SN; Levine MM; Barry EM
    Vaccine; 2009 Apr; 27(18):2426-36. PubMed ID: 19368784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
    [No Abstract]   [Full Text] [Related]  

  • 37. Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.
    Barrigan LM; Tuladhar S; Brunton JC; Woolard MD; Chen CJ; Saini D; Frothingham R; Sempowski GD; Kawula TH; Frelinger JA
    Infect Immun; 2013 Jun; 81(6):2028-42. PubMed ID: 23529616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge.
    Cole LE; Yang Y; Elkins KL; Fernandez ET; Qureshi N; Shlomchik MJ; Herzenberg LA; Herzenberg LA; Vogel SN
    Proc Natl Acad Sci U S A; 2009 Mar; 106(11):4343-8. PubMed ID: 19251656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.
    Dreisbach VC; Cowley S; Elkins KL
    Infect Immun; 2000 Apr; 68(4):1988-96. PubMed ID: 10722593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD; Singh R; Metzger DW
    Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.